Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Glabellar lines |
Dose: Injection – 20 units Frequency: once Duration: approximately 3-4 months Note: Inject 4 units (0.1 mL) into each of 5 sites, 2 in each corrugator muscle and 1 in procerus muscle. More frequent dosing not recommended. |
|
Indication: Canthal lines |
Dose: Injection – 24 units (0.6 mL) Frequency: once Duration: approximately 3-4 months Note: Inject 4 units (0.1 mL) into 3 sites per side (6 total injection points) in the lateral orbicularis oculi muscle (12 units per side). More frequent dosing not recommended. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Blepharospasm Age: greater than or equal to 12 years |
Dose: Intramuscular Injection – 1.25-2.5 units Frequency: May increase dose 2-fold if response to initial treatment dose does not last longer than 2 months Little benefit obtained from injecting greater than 5 units per site Note: less than 200 units in 30 days |
|
Indication: Strabismus Age: greater than or equal to 12 years |
Dose: Intramuscular Injection – 1.25-5 units Note: less than 25 units per injection |
Administration
- For medical professional use only
- Must be properly diluted
Side Effect
- Serious adverse reactions were not observed in clinical trials
- The most common adverse reaction was skin rash
- Other reactions such as chills
- muscle cramps
- back pain
- fever
- nausea
- vomiting
- and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human IGIV products
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Selective Immunoglobulin A Deficiency
|
Risk of severe immune reaction
|
|
Prior Severe Reaction to Immunoglobulin
|
Risk of anaphylaxis
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.